The OHR-102 combination arm demonstrated a higher percentage reduction of subretinal hyperreflective material (SHRM) and a greater proportion of patients with total resolution of SHRM compared to the Lucentis monotherapy arm. Importantly, the anatomical benefit seen with OHR-102 combination therapy correlated with the improved vision seen in these patients in the study.
-- End of Phase II Meeting with the FDA -- FDA agreed on a nine month primary efficacy endpoint for the Phase III trials for OHR-102 based on improvement in visual acuity, defined by gains of greater-than or equal to 3 lines at 9 months.
-- FDA agreed on a nine month primary efficacy endpoint for the Phase III trials for OHR-102 based on improvement in visual acuity, defined by gains of greater-than or equal to 3 lines at 9 months.
-- Two identical Phase III confirmatory studies will be required, designed to measure the efficacy of combination therapy with OHR-102 eye drops plus Lucentis injections compared with Lucentis monotherapy. The Company expects to begin these studies in the first half of calendar 2015.
Sentiment: Strong Buy
Appears you short the stocks with the best future drugs in their pipeline. I am sure you will be saying the same old phase when PPHM stock is much higher soon. Just profit taking now and price will move forward with their pipeline growth...
Sentiment: Strong Buy
You know when hiring goes up, means business is growing. More new trials, drugs, and manufacturing growth. It's all been stated by management....Just the Phase III huge trial alone, is a major step going forward for the company. When PPHM breaks out, it will be one h of a breakout.
A lot of these small underpriced biotech companies are now starting to double and triple their stock prices on just preclinical and phase I drugs.
PPHM has had many great positives with little response. So when that time comes at some point, PPHM will open the window of opportunity to prove what they have been saying and working on undercover, will surprise the daylights out of many unbelievers that rant their unsupported stories here, day after day.
Sentiment: Strong Buy
2.00 Options Volume stronger today for April 17 and July 17. Maybe that's why PPHM green. Someone is playing games today with the price. Buying or covering low and bringing the price up?
Yahoo Finance closed down PPHM message board last several days trying to get rid of the short hustlers that love to create stories for their own benefits. At least there is another way to get in besides going through Yahoo finance list.
Sentiment: Strong Buy
You are so right about these negative bashers. They are here for their own agenda...To misguide and sway investors to the negative side with their corrupted misinformation. It's like someone hired a group to keep these bashers here to try to cover up the true science and the remarkable progress PPHM has come in the recent years.
PPHM has the making of a major pipeline of drugs that will extend the health/life of our future generation. PPHM'S Phase III trial is proof that the science will become a major breakthrough for their future of achieving success.
Sentiment: Strong Buy
Well pt Boy ..you sure have it wrong. PEIX became the NEW PEIX when they reorganized and paid off all debts and now owns 100% of its assets plus. PEIX will become the 4th largest Ethanol company in the US when merger is finalized soon.....
Besides having a overnight growth soon, You never know what other new announcements could surprise.
Sentiment: Strong Buy
Was the 17 mil shares ever purchased yet for Aurigene's purchase? That could make a volume difference. Sais it was going to happen immediately.
Sentiment: Strong Buy
CSM employees mislabeled vials in one trial and messed up a trial previously for another company. They should be held accountable, especially when it nearly destroyed a small company like PPHM.
This happens more frequently than it should and of course they better pay dearly for any hardship and losses they caused to PPHM and put on sec watch.
Yes, the stock can take a 95 degree turn and blow real fast with news from FDA, Offers, PPHM and with more analyst coming forward. We already have 2 analyst recently giving PPHM a 6 to 12 Month price target of $4 to $5. And that's not including future news, that could knock every short on the floor in a heartbeat......
Life can be short and scary, holding PPHM shares short at the bottom. See what happened to oil stocks. When things hit bottom they can turn without notice.
Reasong this information is news (and Big News) is because CEO is Presenting their findings at the Keystone Tumor Immunology: Multidisciplinary Science Driving Combination Therapy meeting being held February 8-13, 2015 in Banff, Alberta, Canada.
These data, further validating the immune-stimulatory mechanism of bavituximab, are outlined in an oral and poster presentation by Bruce Freimark, Ph.D., director, preclinical oncology research at Peregrine, to be made at the Keystone Tumor Immunology: Multidisciplinary Science Driving Combination Therapy meeting being held February 8-13, 2015 in Banff, Alberta, Canada. Peregrine's lead PS-targeting antibody, bavituximab, is currently being evaluated in second-line non-small cell lung cancer (NSCLC) as part of the SUNRISE pivotal Phase III clinical trial.
About Keystone Symposia
Keystone Symposia serve as a catalyst for the advancement of biomedical and life sciences by connecting scientists within and across disciplines at conferences and workshops held at venues that create an environment conducive to information exchange, generation of new ideas and acceleration of applications that benefit society.
Links to these presentations can be found on the front page of Peregrine's website
So, what are Americans doing with some of the money they're saving from cheap gas? They are buying more fuel.
Plunging prices are encouraging Americans to drive more often and buy more trucks. At the same time, faster economic growth and a big influx in hiring over the past year means more Americans are now taking part in the daily commute.
The result: sharply higher demand for gasoline, argues Nicholas Colas, chief market strategist at ConvergEx.
"We've finally discovered where American consumers are spending some of the savings from lower gasoline prices: they are buying more gasoline," he said in a new report.
For one thing, Colas points out the amount of gasoline supplied to the U.S. market was up 6.3% in January compared with a year earlier.
What's more, the number of miles Americans drive annually was on track to surpass 3 billion in 2014 for the first time since a record 3.04 trillion in 2007 -- the year before the Great Recession started. (The government estimates miles driven via thousands of electronic sensors on main public roads.)
It really shouldn't come as a surprise that Americans drive more when gasoline prices fall. That is always been the case. And an improving economy has accelerated the trend.
In 2014, for example, the U.S. added 3.1 million jobs. More than half were generated in the final six months of the year, just as gasoline prices began to free fall.
What that translates into is many as 2.25 million new commuters. How do you get to that figure? Well, a 2013 report by the U.S. Census estimated that 76% of Americans drive to work alone. (An additional 11% ride in a car with someone else.)
Spending at gas stations appears to support the idea that car drivers are putting more fuel in their vehicles even as prices fall. The retail cost of regular gas fell by about 37% from July through December, but U.S. sales at gas stations dropped a smaller 25%.
The dramatic drop in gasoline prices -- to less than $2 a gallon in many parts of the country -- is also boosting sales of less fuel efficient trucks. GM, for example, said sales of trucks and crossovers were up 42% in January vs. a year earlier. The release of the new Colorado midsize pickup helped perk up GM sales, but other auto makers also reported double-digit percentage gains in truck purchases.
One thing that is had little impact on overall American driving habits is fuel efficiency standards, Colas argues. Dividing miles driven by gasoline consumption suggests the average vehicle gets about 20 to 21 miles per gallon today, virtually unchanged since 1980.
While battery-operated cars and hybrids get a lot of ink, sales of trucks have soared compared with 35 years ago to easily outweigh the impact of more fuel-efficient vehicles on the road today.
PPHM is hinting that there is remarkable future in their drug portfolio and especially their phase III trial.
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today announced preclinical data presentations showing that the PS-targeting antibody equivalent to bavituximab combined with an anti-PD-1 antibody displayed statistically significant improvement in tumor fighting immune cells, activation signals and cytokines in a model of melanoma compared to anti-PD-1 alone. Moreover, cells that suppress the immune system from recognizing tumors, such as myeloid-derived suppressor cells (MDSCs), were reduced by more than 40% in the combination with the PS-targeting antibody versus anti-PD-1 alone. These data, further validating the immune-stimulatory mechanism of bavituximab, are outlined in an oral and poster presentation by Bruce Freimark, Ph.D., director, preclinical oncology research at Peregrine, to be made at the Keystone Tumor Immunology: Multidisciplinary Science Driving Combination Therapy meeting being held February 8-13, 2015 in Banff, Alberta, Canada. Peregrine's lead PS-targeting antibody, bavituximab, is currently being evaluated in second-line non-small cell lung cancer (NSCLC) as part of the SUNRISE pivotal Phase III clinical trial.
These data build on our growing body of encouraging combination data and strengthen our clinical development plans as we evaluate the direction of combination therapy trials utilizing bavituximab and other checkpoint inhibitors" said Jeff T. Hutchins, Ph.D., vice president of preclinical research at Peregrine. "Our goals are to modify a tumor environment that allows more patients to respond to conventional and immune therapy. As the tumor environment switches from immuno-suppressive to immuno-stimulatory with bavituximab treatment, we believe the addition of other checkpoint inhibitors, like anti-PD-1, may increase the number of patients responding to therapy."
In the presentations titled: "Antibody-Mediated Blockade of Phosphatidylserine Enhances the Anti-Tumor Activity of Immune Checkpoint Inhibitors by Affecting Myeloid-Derived Suppressor Cells (MDSC) and Lymphocyte Populations in the Tumor Microenvironment", Dr. Freimark and his research group, along with colleagues from the University of Texas Southwestern Medical Center led by Xianming Huang, Ph.D., demonstrate that in immunocompetent preclinical models of breast cancer and melanoma, the combination of PS-targeting antibodies and anti-CTLA-4 and anti-PD1 antibodies demonstrate statistically significant anti-tumor responses than either anti-CTLA-4 or anti-PD-1 antibody alone. New data presented show statistically significant changes in levels of tumor infiltrating lymphocytes (TILs), a type of white blood cell implicated in killing tumor cells, in the PS-targeting and anti-PD-1 combination group over single treatment alone in a melanoma model. Specifically, data show increases in a number of markers used to determine immune activation, including CD3 and CD8 cells expressing PD-1, Lag-3 and CD137 (4-1BB). Furthermore, data show that CD8 T cells in the tumor had increased production of IFN-gamma and TNF-a, both known to assist in promoting immune activation and Granzyme-B which is involved in direct tumor killing.
eregrine Pharmaceuticals (NASDAQ:PPHM) has received a Outperform rating from research analysts at Zacks with a rating of 1. The company has been rated an average of 1 by 2 Wall Street Analysts. 2 analysts have added the counter in their list of strong buys.
Wall Street Pulse: Peregrine Pharmaceuticals (NASDAQ:PPHM) shares are expected to touch $4.5 in the short term. This short term price target has been shared by 2 analysts. However, the standard deviation of short term price estimate has been valued at 0.71. The target price could hit $5 on the higher end and $4 on the lower end.The information is based on average recommendation on company rating and price target for short term (6 to 12 months) .
Peregrine Pharmaceuticals (NASDAQ:PPHM) : Strong bullish mood helped the shares of Peregrine Pharmaceuticals (NASDAQ:PPHM) appreciate in value. The share price gained 0.02 points or 1.61% to close at $1.26 with 1,390,070 shares exchanging hands. The trading began on a bullish sentiment but no considerable downsides were seen throughout the day; the intraday low was registered at $1.22. However, the shares hit an intraday high of $1.26. The previous close of the share price was $1.24. Peregrine Pharmaceuticals (NASDAQ:PPHM) has a market cap of $229 million and the number of outstanding shares is calculated to be 182,081,000. The 52-week low of the share price is $1.19.
Peregrine Pharmaceuticals (NASDAQ:PPHM) reported a drop of 5.2% or 580,136 shares in its short interest. The short figure came in at 5.9% of the total floats. The average daily volume of 1,462,226 shares suggests that the days to cover 10,646,463 short positions, as on January 15,2015, will be 7. On December 31,2014, the short interest was 11,226,599 shares.
Not sure if any of you saw this write up. This is where PPHM share price should be at now or near term $3 to $5. Something or Someone are holding this stock price down...? PPHM has income from a manufacturing plant, a huge Phase III trial moving forward along with other Phase I and II trials etc...
Sure are ranting a lot lately. Guess you love to play the negative guy roll for your gain. Even thou it's here say, make up babble and make believe nonsense.
many more new orders and future income. The manufacturing plant AVID Helps FUND PPHM trials. PPHM is not just a one shot pony, they are moving forward into several cancer phase trials 1, 11, and a huge phase III fast track trial with many preliminary trials in the making.
PPHM is moving much more faster ahead with their trials than they ever did in the past years.
Let all those naysayer babies cry on their own pillow, cause all their trying to do is create a negative board and keep you from buying into a company who may have some very major great future drugs in the not so far off future.
Look for One drug after another as the trials continue moving forward. That's how small companies become bigger companies, by expanding their manufacturing and drug portfolio.
When and if the right deal comes along, PPHM will partner. But It may be they don't want to give up any cheap deals until the trials are further along or completed.
Now about the share price, seems like many times share or money deals are being made or even some major news to be released along the way. That can cause the lower share price by manipulation until the deal or news is out. Anyway, that's my view of the situation.
Looks like Peregrine is moving forward in their trials and manufacturing plant expansion...with 22 job listings.....
Was hit hard last 2 days. Could be because common was $3 and now below $1.50 at time of Preferred offer of $25. Preferred was overvalued a lot vs common. Now they are both closer to equal. Preferred dividend is now paying over 13% interest. Dividend very Appealing...
Looks like Someone is wanting to buy cheap shares before positive news...Keeping stock price below $3 will also keep less shares to be exchanged for common. As there are more trial results and each trial moves forward, it will be harder to keep share prices low.
When there are deals being made with whomever, stock prices usually go way lower than there normal low while the deal makers are accumulating for profit before major news. Now you can put it to your imagination what kind of news will come out......in the near future.
Sounds like some here are trying their hardest to sway your thinking to the negative side by transposing information they come up with into the worst scenario Outlandish theories.
It's ok to look at what (Could) happen in the future negative and positive. But, to try to be one sided and transpose information with theories saying it happening, is going to far. Everyone has theories, but until they actually happen, you can not say it is happening unless there is FULL proof.